Corticosteroid
Eczema topicals.
Treatment groups
Potency is specific to the ingredient, concentration and vehicle.
Vehicle
Corticosteroid contact allergyA · B · C · D1 · D2
Delayed contact allergy; separate from potency.
Select two entries to review their reported structural relationship.
Browse by structural class
Traditional overlaps
A with D2; budesonide (B) with D2. These patterns are incomplete.
Potency, vehicle, age and search filters still apply.
A guide, with limits
A different class does not establish tolerance. Patch testing should assess the suspected steroid, candidate alternatives and relevant vehicle ingredients.
In a Mayo Clinic series of 5,637 patients, patch-test copositivity did not reliably follow these groups. Copositivity does not prove cross-reactivity.
These groups do not predict immediate corticosteroid reactions.
Corticosteroid
Corticosteroid
0.05% creamSpectro EczemaCare
Corticosteroid
Corticosteroid
Corticosteroid
CorticosteroidHistorical US Dermatop.e · © 2005 GS
0.1% emollient creamDermatop
Corticosteroid
Corticosteroid
Corticosteroid
CorticosteroidIndian reference · Propynate NF
0.025% creamPropaderm
CorticosteroidRepresentative · UK cream pack
Corticosteroid
CorticosteroidHistorical US pack · © 2005 GS
Corticosteroid
0.01% topical oilDerma-Smoothe/FS
Calcineurin inhibitorInternational packaging
Tacrolimus
0.03% ointment
Apply a thin layer twice daily, morning and evening, for active disease
2+ years
Calcineurin inhibitor
Tacrolimus
0.1% ointment
Apply a thin layer twice daily, morning and evening, for active disease
16+ years
Calcineurin inhibitor
Pimecrolimus
1% cream
Apply a thin layer twice daily; stop when the skin clears
3+ months
PDE4 inhibitor
Crisaborole
2% ointment
Apply a thin layer to affected areas twice daily during active disease
3+ months
PDE4 inhibitorUS packaging
Roflumilast
0.15% cream
Apply once daily to affected areas and rub in completely
6+ years
PDE4 inhibitorRepresentative · US 0.05% tube
Roflumilast
0.05% cream
Apply once daily to affected areas and rub in completely
2 to under 6 years
JAK inhibitor
Ruxolitinib
1.5% cream
Apply a thin layer twice daily, at least 8 hours apart, to no more than 20% body surface area
2+ years · AD
AhR agonist
Tapinarof
1% cream
Apply a thin layer once daily to clean, dry affected skin
2+ years · AD
JAK inhibitorGerman pack · 60 g
Delgocitinib
2% cream · 20 mg/g
Apply a thin layer to affected hands and wrists twice daily, about 12 hours apart
18+ years